MedTrace Logo

Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma

NCT02646137 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-01-09

No results posted yet for this study

Summary

Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.

Conditions

Interventions

DRUG

Transarterial chemoembolization (TACE)

TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles

PROCEDURE

Radiofrequency ablation combined with TACE

Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition

PROCEDURE

Microwave ablation combined with TACE

Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Elshazly Sheta, Professor · Hepatology and gastroenterology dept.-Tanta

  • Ferial El-kalla, Professor · Division of Gastroenterology and Hepatology- Tanta

  • Mohamed Elgharib, Professor · Interventional radiology - Ainshams university- Egypt

  • Abdelrahman kobtan, Consultant · liver diseases dept.-Tanta university hospital

  • Mohamed Elhendawy, Consultant · liver diseases dept.-Tanta university hospital

  • Sherief Abd-Elsalam, Consultant · Hepatology and gastroenterology dept.-Tanta

  • Ibrahim Amer, Consultant · Liver diseases and gastroenterology dept.-Tanta university hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646137 on ClinicalTrials.gov